Table Info

Table 1.

Main vaccine types and phase 3–4 candidates as of June 2021 [50]

Vaccine platform description	Number of candidate vaccines	%	Number of doses	Schedule	Route of administration	Developers (Candidate vaccine type)	Phase
mRNA vaccines	16	16	2	Day 0 + 28	i.m	Moderna (mRNA 1273)	Phase 4^*
			2	Day 0 + 2	i.m.	Pfizer/BioNTech (BNT162b2)	Phase 4^*
			2	Day 0 + 28	i.m.	CureVac AG (CVnCoV)	Phase 3
			2	Day 0 + 14or Day 0 + 28	i.m.	Academy of MilitaryScience (AMS)/(ARCoV)	Phase 3
Vectorvaccines	18	18	1–2	Day 0 + 28	i.m.	Oxford/Astra Zeneca (ChAdOx1)	Phase 4^*
			1	Day 0	i.m.	CansinoBiologicalInc. (Ad5-nCoV)	Phase 4
			2	Day 0 + 21	i.m.	Sputnik V (Gam-COVID-Vac) (rAd26-S+rAd5-S)	Phase 3
			1–2	Day 0 or Day 0 + 56	i.m.	Johnson&Johnson/ Janssen Pharmaceutical (Ad26. COV2.S)	Phase 3^*
			1	Day 0	i.m.	ReiThera + Leukocare + Univercells (GRAd-COV2)	Phase 2/3
Inactivated virus	16	16	2	Day 0 + 14	i.m.	CoronaVac (Sinovac)	Phase 4^*
vaccines			2	Day 0 + 21	i.m.	Sinopharm/WIBP-CorV	Phase 3^*
			2	Day 0 + 28	i.m.	Institute of Medical Biology (verocells)	Phase 3
			2	Day 0 + 21	i.m.	Research Institute for Biological Safety Problems (QazCovid-in)	Phase 3
			2	Day 0 + 14	i.m.	Bharat Biotech(BBV152)	Phase 3
			2	Day 0 + 28	i.m.	Shenzhen Kangtai Biological Products (Verocell)	Phase 3
			2	Day 0 + 21	i.m.	Valneva, National Institute for Health Research, United Kingdom (VLA2001)	Phase 3
			2	Day 0 + 21	i.m.	Erciyes University and the health instutes of turkey (TUSEB) (TURKOCAV)	Phase 3
			2	Day 0 + 14	i.m.	Shifa Pharmed Industrial Co	Phase 2/3
DNA vaccines	10	10	2	Day 0 + 21	i.m.	Inovio Pharmaceuticals (INO-4800+electroporation)	Phase 2/3
			2	Day 0 + 14	i.m.	AnGes + TakaraBio + Osaka University (AG0301-COVID19)	Phase 2/3
			3	Day 0 + 28+ 56	i.d.	Zydus Cadila (nCovvaccine)	Phase 3
Protein subunit	32 vaccines	31	2	Day 0 + 21	i.m.	Novavax (NVX-CoV2373)	Phase 3
			2–3	Day 0 + 28or Day 0 + 28 + 56	i.m.	Anhui Zhifei Longco (ZF2001-Recombinant SARS-CoV-2 Vaccine)	Phase 3
			2	Day 0 + 21	i.m.	Sanofi Pasteur + GSK (VAT00002)	Phase 3
			2	Day 0 + 21	i.m.	Clover Biopharmaceuticals Inc./GSK/Dynavax (SCB-2019 + AS03 or CpG 1018 adjuvant plus)	Phase 2/3
			2	Day 0 + 28	i.m.	Instituto Finlay de Vacunas (FINLAY-FR-2 anti-SARS-CoV-2 Vaccine)	Phase 3
			2	Day 0 + 21	i.m.	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”(EpiVacCorona)	Phase 3
			3	0 + 14 + 28 or Day 0 + 28 + 56	i.m.	Center for Genetic Engineering and Biotechnology (CIGB-66)	Phase 3
Virus like particle vaccines	5	5	2	Day 0 + 21	i.m.	Medicago Inc. (CoVLP)	Phase 2/3

As of 3 June 2021, WHO has assessed that it meets the necessary criteria for safety and efficacy against COVID-19. %: clinical pass rate

Declarations

Author contributions

SH and HD wrote the manuscript; SH and HD conceived, wrote, and revised the manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424–32. [DOI] [PubMed] [PMC]

Salute MD. Nuovo coronavirus [Internet]. Roma: I: Governo-Repubblica Italiana; 2020. c2021 [cited 2021 May 5]. Available from: http://www.salute.gov.it/nuovocoronavirus

Del Rio C, Malani PN. 2019 novel coronavirus-important information for clinicians. JAMA. 2020;323:1039–40. [DOI] [PubMed]

Salute MD. Covid-19-Situazione in Italia [Internet]. Roma: I: Governo-Repubblica Italiana; 2020. c2021 [cited 2021 May 5]. Available from: http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5351&area=nuovoCoronavirus&menu=vuoto

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020;7:11. [DOI] [PubMed] [PMC]

Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–23. [DOI] [PubMed] [PMC]

World Health Organization [Internet]. WHO coronavirus (COVID-19) dashboard, 2021. [cited 2021 May 5]. Available from: https://covid19.who.int/

Mavi D, İnkaya AÇ. COVID-19: immün patogenez. FLORA. 2020;25. Turkce. [DOI]

Masihi KN. Fighting infection using immunomodulatory agents. Expert Opin Biol Ther. 2001;1:641–53. [DOI] [PubMed]

10.

Ou X, Liu Y, Lei X. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620. [DOI] [PubMed] [PMC]

11.

Kahraman EP, Altındis M. COVID-19 asıları pandemide sona dogru? J Biotechnol and Strategic Health Res. 2020;4:240–9. Turkce. [DOI]

12.

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020;14:1011–9. [DOI] [PubMed] [PMC]

13.

Yi Y, Lagniton PN, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16:1753–66. [DOI] [PubMed] [PMC]

14.

Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VY, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14:3822–35. [DOI] [PubMed] [PMC]

15.

Kannan S, Ali PSS, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019)—recent trends. Eur Rev Med Pharmacol Sci. 2020;24:2006–11. [DOI] [PubMed]

16.

Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250:271–8. [DOI]

17.

Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z, et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35:1545–9. [DOI] [PubMed] [PMC]

18.

Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13:667–73. [DOI] [PubMed] [PMC]

19.

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372. [DOI] [PubMed] [PMC]

20.

Hindistan S, Kazak A. Vaccination studies against COVID-19 agent: current status. Bezmialem Science. 2020;8:145–52.

21.

Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164. [DOI] [PubMed] [PMC]

22.

Lissenberg A, Vrolijk MM, van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier PJ, et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hem agglutinin esterase protein display reduced fitness in vitro. J Virol. 2005;79:15054–63. [DOI]

23.

Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol. 2010;84:3134–46. [DOI] [PubMed] [PMC]

24.

De Haan CA, de Wit M, Kuo L, Montalto-Morrison C, Haagmans BL, Weiss SR, et al. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. Virology. 2003;312:395–406. [DOI] [PubMed] [PMC]

25.

Ruch TR, Machamer CE. The coronavirus E protein: assembly and beyond. Viruses. 2012;4:363–82. [DOI] [PubMed] [PMC]

26.

Escors D, Ortego J, Enjuanes L. The membrane M protein of the transmissible gastroenteritis coronavirus binds to the internal core through the carboxy-terminus. Adv Exp Med Biol. 2001;494:589–93. [DOI] [PubMed] [PMC]

27.

Khailany AR, Safdar M, Ö zaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682. [DOI] [PubMed] [PMC]

28.

Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009;106:5871–6. [DOI] [PubMed] [PMC]

29.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8. [DOI] [PubMed] [PMC]

30.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. [DOI] [PubMed] [PMC]

31.

Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127:110195. [DOI] [PubMed] [PMC]

32.

Yip MS, Leung HL, Li PH, Cheung CY, Dutry I, Li D, et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J. 2016;22 Suppl 4:25–31. [PubMed]

33.

Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451:208–14. [DOI] [PubMed] [PMC]

34.

Liu J, Wu P, Gao F, Qi J, Kawana-Tachikawa A, Xie J, et al. Novel immunodominant peptide presentation strategy: a featured HLAA*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. J Virol. 2010;84:11849–57. [DOI] [PubMed] [PMC]

35.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027–34. [DOI] [PubMed] [PMC]

36.

Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A. 2018;115:E1012–21. [DOI] [PubMed] [PMC]

37.

Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VC, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26:1478–88. [DOI] [PubMed] [PMC]

38.

Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971–7.e3. [DOI] [PubMed] [PMC]

39.

Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofman C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020;383:1085–7. [DOI] [PubMed] [PMC]

40.

Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4. [DOI] [PubMed]

41.

Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383:1724–34. [DOI] [PubMed] [PMC]

42.

Lee JS, Kim SY, Kin TS, Hong KH, Ryoo NH, Lee J, et al. Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019. Clin Infect Dis. 2020;73:e3002–8. [DOI] [PubMed] [PMC]

43.

Carillo J, Izquierdo-Useros N, Avila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2021;538:187–91. [DOI] [PubMed] [PMC]

44.

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–501.e15. [DOI] [PubMed] [PMC]

45.

Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–62. [DOI] [PubMed]

46.

Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2 reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270–4. [DOI] [PubMed]

47.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158–68.e14. [DOI] [PubMed] [PMC]

48.

Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, et al. Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion, France. Emerge Infect Dis. 2021;27:113–21. [DOI] [PubMed]

49.

Azalp A. COVID-19 vaccines: light at the end of the tunnel. Archives Medical Review Journal. 2020; 9:94–100. [DOI] [PubMed] [PMC]

50.

World Health Organization [Internet]. COVID-19 vaccine tracker and landscape. [cited 2021 May 16]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

51.

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595–606. [DOI] [PubMed] [PMC]

52.

Polack FP, Thomas SJ, Kitchin N, Ablason J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. [DOI] [PubMed] [PMC]

53.

World Health Organization [Internet]. Background document on the mRNA vaccine BNT162b2 (Pfizer/ BioNTech) against Covid-19. c2021 [cited 2021 May 17]. Available from: https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19

54.

Shimabukoro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325:780–1. [DOI] [PubMed]

55.

Baden LR, El Sahyl HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. [DOI] [PubMed] [PMC]

56.

Centers for Disease Kontrol and Prevention [Internet]. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna Covid-19 vaccine—United States, December 21, 2020-January 20, 2021. [cited 2021 Jun 25]. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm?s_cid=mm7004e1_w

57.

World Health Organization [Internet]. Interim recommendations for use of the Moderna mRNA-1273 vaccine against Covid-19. c2021 [cited 2021 Jun 25]. Available from: https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19

58.

Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580:576–7. [DOI] [PubMed]

59.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK. Lancet. 2021;397:99–111. [DOI] [PubMed] [PMC]

60.

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–54. [DOI] [PubMed] [PMC]

61.

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost Covid-19 vaccine in two formulations: two open, non-randomised phase 1/2studies from Russia. Lancet. 2020;396:887–97. [DOI] [PubMed] [PMC]

62.

Logunov DY, Dolzhikova IV, Shcheblyakov D, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost Covid-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81. [DOI] [PubMed] [PMC]

63.

Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824–35. [DOI] [PubMed] [PMC]

64.

jnj.com [Internet]. Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—first single-shot vaccine in fight against global pandemic. c1997–2021 [cited 2021 Jun 26]. Available from: https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic

65.

World Health Organization [Internet]. The Janssen Ad26.COV2.S COVID-19 vaccine: what you need to know. c2021 [cited 2021 Jun 16]. Available from: https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know

66.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healty adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92. [DOI] [PubMed] [PMC]

67.

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healty adults aged 60 years and older: a randomised, double-blind, plasebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:803–12. [DOI] [PubMed] [PMC]

68.

T.C Sağlık Bakanlığı [Internet]. COVID-19 aşısı bilgilendirme platformu. c2021 [cited 2021 May 13]. Available from: https://covid19asi.saglik.gov.tr/TR-77693/covid-19-asisi.html

69.

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020;21:39–51. [DOI] [PubMed] [PMC]

70.

World Health Organization [Internet]. The Sinopharm COVID-19 vaccine: what you need to know. [cited 2021 May 5]. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know

71.

Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21:950–61. [DOI] [PubMed] [PMC]

72.

Mammen P Jr, Tebas P, Agnes J, Giffear M, Kraynyak KA, Blackwood E, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv 21256652 [Preprint]. c2021 [cited 2021 May 20]. Available from: https://doi.org/10.1101/2021.05.07.21256652

73.

Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296. [DOI] [PubMed]

74.

ir.novavax.com [Internet]. Novavax: Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. [cited 2021 Jun 25]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

75.

Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21:1107–19. [DOI] [PubMed] [PMC]

76.

Gobeil P, Pillet S, Séguin A, Boulay I, Mahmood A, Vinh DC, et al. Phase 2 randomized trial of an AS03 adjuvanted plant-based virus-like particle vaccine for Covid-19 in healthy adults, older adults and adults with comorbidities. medRxiv 21257248 [Preprint]. c2021 [cited 2021 May 25]. Available from: https://doi.org/10.1101/2021.05.14.21257248